ArticleESMO gastrointestinal oncology2025

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

B C Köhler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.